Hospira's Angiomax Generic At Risk As Contract Manufacturing Gets Legal Reprieve
Federal Circuit en banc court reverses panel decision, giving The Medicines Company chance to prove infringement and get Hospira's generic off the market.
You may also be interested in...
Hospira's generic does not infringe The Medicine Company's patented method of making Angiomax, US Federal Circuit finds, but leaves question of whether TMC's distribution agreement covers manufacturing process for the district court to decide.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.